Envista (NVST) Stock Price, News & Analysis

Company Overview

Envista Holdings Corporation, headquartered in Brea, California, is a global dental products company formed in 2019 following a spin-off from Danaher Corporation. As a standalone entity, Envista focuses on developing, manufacturing and marketing a comprehensive portfolio of dental devices and consumables designed to support dental professionals throughout the treatment process. The company’s mission centers on advancing oral health by delivering innovative solutions that enhance treatment outcomes and practice efficiency.

Envista’s product offerings span several key areas of dentistry. In the implants segment, the company provides a range of dental implant systems, restorative components and guided surgery solutions. Its Equipment & Consumables division includes ultrasonic scalers, dental handpieces, infection prevention products and restorative materials. The digital solutions business develops imaging systems, CAD/CAM software and intraoral scanners to facilitate digital workflows, while the orthodontics unit offers brackets, wires, clear aligners and related accessories for orthodontic treatment. The Specialty Products group encompasses an array of endodontic, periodontal and restorative tools and materials.

With a presence in over 100 countries, Envista operates a global manufacturing and supply chain network complemented by innovation centers and regional sales offices. This international footprint enables the company to address diverse market needs, support local distributors and deliver timely service and training to dental professionals. Envista’s research and development teams collaborate closely with clinicians to drive product enhancements and introduce next-generation technologies.

The company is led by President and Chief Executive Officer Amir Aghdaei, supported by a seasoned executive leadership team with deep expertise in medical devices and dental markets. Envista places strong emphasis on customer engagement, quality management and strategic partnerships to foster long-term growth. By leveraging its broad product portfolio and global reach, Envista aims to shape the future of dentistry and improve oral health outcomes worldwide.

Key Stats

• Today's Range: $20.02 to $20.50
• 50-Day Range: $15.96 to $20.39
• 52-Week Range: $14.22 to $23.00
• Volume: 1.00 million shs
• Average Volume: 2.50 million shs
• Market Capitalization: $3.46 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.23
• Consensus Rating: Hold

Envista Stock Analysis - MarketRank™

Envista scored higher than 75% of companies evaluated by MarketBeat, and ranked 754th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Envista has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 4 buy ratings, 9 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Envista has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 21.00%

Earnings Growth

Earnings for Envista are expected to grow by 21.00% in the coming year, from $1.00 to $1.21 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Envista is -3.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Envista is -3.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Envista has a PEG Ratio of 1.28. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Envista has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.08% of the float of Envista has been sold short.

Short Interest Ratio / Days to Cover

Envista has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Envista has recently decreased by 1.45%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Envista does not currently pay a dividend.

Dividend Growth

Envista does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.8 / 5
• Environmental Score: -0.95

Percentage of Shares Shorted

6.08% of the float of Envista has been sold short.

Short Interest Ratio / Days to Cover

Envista has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Envista has recently decreased by 1.45%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.74

News Sentiment

Envista has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Envista this week, compared to 6 articles on an average week.

Search Interest

Only 2 people have searched for NVST on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added Envista to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Envista insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.30% of the stock of Envista is held by insiders.

NVST Stock Analysis - Frequently Asked Questions

How have NVST shares performed this year?

Envista's stock was trading at $19.29 on January 1st, 2025. Since then, NVST stock has increased by 5.7% and is now trading at $20.39.

How were Envista's earnings last quarter?

Envista Holdings Corporation (NYSE:NVST) released its quarterly earnings results on Thursday, May, 1st. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.20 by $0.04. Envista's revenue was down 1.1% on a year-over-year basis.
Read the conference call transcript.

When did Envista IPO?

Envista (NVST) raised $603 million in an IPO on Wednesday, September 18th 2019. The company issued 26,800,000 shares at $21.00-$24.00 per share. J.P. Morgan, Goldman Sachs and Morgan Stanley acted as the underwriters for the IPO and Baird, Evercore ISI, Jefferies, BofA Merrill Lynch, Credit Suisse, Stifel and William Blair were co-managers.

How do I buy shares of Envista?

Shares of NVST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Envista own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Envista investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), The RMR Group (RMR) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 7/03/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:NVST
• CIK: 1757073
• Web: www.envistaco.com
• Phone: 714-817-7000
• Fax: 714-817-5450
• Employees: 12,700
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $20.23
• High Stock Price Target: $23.00
• Low Stock Price Target: $16.00
• Potential Upside/Downside: -0.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 20.39
• P/E Growth: 1.27
• Net Income: -$1.12 billion
• Net Margins: -44.90%
• Pretax Margin: -43.57%
• Return on Equity: 4.07%
• Return on Assets: 2.25%

Debt

• Debt-to-Equity Ratio: 0.43
• Current Ratio: 2.12
• Quick Ratio: 1.82

Sales & Book Value

• Annual Sales: $2.50 billion
• Price / Sales: 1.38
• Cash Flow: $1.69 per share
• Price / Cash Flow: 12.05
• Book Value: $17.05 per share
• Price / Book: 1.20

Miscellaneous

• Outstanding Shares: 169,487,000
• Free Float: 167,284,000
• Market Cap: $3.46 billion
• Optionable: Optionable
• Beta: 1.00